Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Claudia Lasagni, Laura Bigi, Andrea Conti & Giovanni Pellacani. (2018) Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. Journal of Dermatological Treatment 29:sup2, pages 5-8.
Read now
Read now
M. Magnano, C. Loi, A. Patrizi, P. Sgubbi, R. Balestri, G. Rech, L Tasin, C. R. Girardelli, A. Conti, G. Odorici, A. Campanati, A. M. Offidani & F. Bardazzi. (2018) Secukinumab in multi-failure psoriatic patients: the last hope?. Journal of Dermatological Treatment 29:6, pages 583-585.
Read now
Read now
Laura Sawyer, Iain Fotheringham, Emily Wright, Najeeda Yasmeen, Carl Gibbons & Anders Holmen Møller. (2018) The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. Journal of Dermatological Treatment 29:6, pages 557-568.
Read now
Read now
Articles from other publishers (8)
E.V. Svechnikova, Z.B. Marshani, K.A. Fomin & E.Yu. Evdokimov. (2021) Genetically engineered biological drugs in psoriasis treatment in the COVID-19 pandemic. Klinicheskaya dermatologiya i venerologiya 20:5, pages 95.
Crossref
Crossref
Nihal Bekkali, Corinne Simon, Raphaelle Binois & Éric Estève. (2020) Urticaire sévère avec récidive compliquée d’angiœdème sous sécukinumab : à propos d’un cas. Therapies 75:5, pages 509-511.
Crossref
Crossref
Laura M. Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg & Richard B. Warren. (2019) Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLOS ONE 14:8, pages e0220868.
Crossref
Crossref
Ros Wade, Alessandro Grosso, Emily South, Claire Rothery, Pedro Saramago, Laetitia Schmitt, Kath Wright & Stephen Palmer. (2018) Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. PharmacoEconomics 37:2, pages 131-139.
Crossref
Crossref
Tania Marusia Capusan, María Herrero-Moyano, Constanza Romina Martínez-Mera, Al Walid Freih-Fraih & Esteban Dauden. (2018) Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?. JAAD Case Reports 4:6, pages 521-523.
Crossref
Crossref
Aikaterini Tsentemeidou, Timoleon-Achilleas Vyzantiadis, Aikaterini Kyriakou, Dimitrios Sotiriadis & Aikaterini Patsatsi. (2017) Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: Results of a pilot study. Mycoses 60:12, pages 830-835.
Crossref
Crossref
Christine E Martinez, John B Allen, Frederick H Davidorf & Colleen M Cebulla. (2017) Endogenous endophthalmitis and osteomyelitis associated with interleukin 17 inhibitor treatment for psoriasis in a patient with diabetes. BMJ Case Reports, pages bcr-2017-219296.
Crossref
Crossref
Adriane A Levin & Jeffrey M Sobell. (2017) Update on IL-17 Inhibitors for Psoriasis. Current Dermatology Reports 6:2, pages 121-128.
Crossref
Crossref